AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Bio-Rad Laboratories A: Bollinger Bands Expanding Downward, KDJ Death Cross Indicators Triggered
ByAinvest
Tuesday, Sep 2, 2025 10:33 am ET1min read
According to Bio-Rad Laboratories A's 15-minute chart, the Bollinger Bands are currently expanding downward, and the KDJ indicator has triggered a death cross at 09/02/2025 10:30. This suggests that the market trend is being driven by sellers, with momentum shifting towards the downside and potentially leading to further decreases in stock price.
The liquid biopsy market is poised for substantial growth, with an anticipated market size of USD 7.05 billion by 2030, according to a recent report by ResearchAndMarkets.com [1]. This non-invasive diagnostic tool is expected to grow from USD 4.03 billion in 2025, marking a compound annual growth rate (CAGR) of 11.8%.The liquid biopsy market is segmented by product & service, circulating biomarker type, technology, application, sample type, and end user. Key drivers for this growth include the increasing incidence of cancer, rising healthcare budgets, and advancements in early-stage cancer detection technologies. The market is further segmented by clinical application, with early cancer screening expected to grow at the highest CAGR during the forecast period.
The report highlights the dominance of blood samples in the market, driven by their ease of collection and rich molecular data. The Asia Pacific region is projected to experience the highest growth, driven by factors such as increasing cancer incidence and government-supported screening efforts.
Major players in the liquid biopsy market include Natera, Inc., Guardant Health, Myriad Genetics, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., QIAGEN, Thermo Fisher Scientific Inc., and Bio-Rad Laboratories, among others. These companies are driving market growth through innovation and competition.
According to the report, the liquid biopsy market is influenced by various factors, including drivers such as increasing demand for early cancer detection and restraints such as high costs and regulatory challenges. Opportunities lie in the growing demand for personalized medicine and the development of new technologies.
References:
[1] https://finance.yahoo.com/news/liquid-biopsy-market-trends-industry-093200033.html
[2] https://www.marketbeat.com/instant-alerts/bio-rad-laboratories-nysebio-rating-increased-to-hold-at-zacks-research-2025-08-28/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet